Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating chronic back pain in those who have not had or are ineligible for back surgery.
The US Food and Drug Administration has approved the Proclaim Plus spinal cord stimulation system with FlexBurst360 therapy, which provides personalized coverage at up to six pain points.
Abbott s new Proclaim™ Plus spinal cord stimulation (SCS) system offers the next generation of stimulation therapy, giving physicians the ability to treat.